Intravenous immunoglobulin

(Redirected from IVIG)

Administration

  • Type: Immunologic agent
  • Dosage Forms:
  • Routes of Administration: IV
  • Common Trade Names: Gammagard, Gammar-IV, Gamimune-N, Camunex, Carimune/Panglobulin, Iveegam, Polygam S/D, Sandoglobulin, Venoglobulin, KIOVIG

Note: components of each brand vary

Adult Dosing

Varies depending on formulation

Pediatric Dosing

Varies depending on formulation

Special Populations

Indications

Contraindications

  • Allergy to class/drug
  • Hereditary intolerance to sucrose or fructose
  • Hyperprolinemia
  • IgA deficiency with antibodies
    • all IVIG contain trace IgA
    • Gammagard and Polygram have the least

Adverse Reactions

Serious

  • MI, chest pain
  • Tachycardia
  • Hemolytic anemia
  • Thrombosis, PE
  • Acute renal failure
  • Hyponatremia
  • Aseptic meningitis
  • Transfusion related acute lung injury

Common

  • Hypertension, hypotension
  • Peripheral edema
  • Pruritus, rash, injection site reaction
  • Hyperthermia
  • Nausea, vomiting, diarrhea, abdominal pain
  • Aphthous ulcer
  • Arthralgia, myalgia, backache, headache
  • Dizziness, fatigue
  • Otalgia
  • Asthma, nasal congestion, wheezing, pharyngitis
  • Fever, rigors, shivering
  • Infusion reaction

Pharmacology

  • Half-life: 5-37 days
  • Metabolism:
  • Excretion:

Mechanism of Action

  • Interference with Fc receptors on the cells of the reticuloendothelial system for autoimmune cytopenias and ITP

See Also

References

Authors:

Claire